Literature DB >> 20109740

Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects in 2009.

Scott H Sicherer1, Donald Y M Leung.   

Abstract

This review highlights some of the research advances in anaphylaxis and hypersensitivity reactions to foods, drugs, and insects, as well as advances in allergic skin disease that were reported in the Journal in 2009. Among key epidemiologic observations, several westernized countries report that more than 1% of children have peanut allergy, and there is some evidence that environmental exposure to peanut is a risk factor. The role of regulatory T cells, complement, platelet-activating factor, and effector cells in the development and expression of food allergy were explored in several murine models and human studies. Delayed anaphylaxis to mammalian meats appears to be related to IgE binding to the carbohydrate moiety galactose-alpha-1,3-galactose, which also has implications for hypersensitivity to murine mAb therapeutics containing this oligosaccharide. Oral immunotherapy studies continue to show promise for the treatment of food allergy, but determining whether the treatment causes tolerance (cure) or temporary desensitization remains to be explored. Increased baseline serum tryptase levels might inform the risk of venom anaphylaxis and might indicate a risk for mast cell disorders in persons who have experienced such episodes. Reduced structural and immune barrier function contribute to local and systemic allergen sensitization in patients with atopic dermatitis, as well as increased propensity of skin infections in these patients. The use of increased doses of nonsedating antihistamines and potential usefulness of omalizumab for chronic urticaria was highlighted. These exciting advances reported in the Journal can improve patient care today and provide insights on how we can improve the diagnosis and treatment of these allergic diseases in the future. Copyright 2010 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20109740     DOI: 10.1016/j.jaci.2009.11.031

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  10 in total

Review 1.  Future therapies for food allergies.

Authors:  Anna Nowak-Węgrzyn; Hugh A Sampson
Journal:  J Allergy Clin Immunol       Date:  2011-01-31       Impact factor: 10.793

2.  IL-9(+) IL-10(+) T cells link immediate allergic response to late phase reaction.

Authors:  S-H He; Z-Q Liu; X Chen; C-H Song; L-F Zhou; W-J Ma; L Cheng; Y Du; S-G Tang; P-C Yang
Journal:  Clin Exp Immunol       Date:  2011-04-13       Impact factor: 4.330

3.  A (S)-(+)-decursin derivative, (S)-(+)-3-(3,4-dihydroxy-phenyl)-acrylic acid 2,2-dimethyl-8-oxo-3,4-dihydro-2H,8H-pyrano[3,2-g]-chromen-3-yl-ester, attenuates the development of atopic dermatitis-like lesions in NC/Nga mice.

Authors:  In Sik Kim; Dong-Hee Kim; Chi-Young Yun; Ji-Sook Lee
Journal:  Mol Biol Rep       Date:  2013-01-05       Impact factor: 2.316

4.  Inhibitory effect of farnesylthiosalicylic acid on mediators release by mast cells: preferential inhibition of prostaglandin D(2) and tumor necrosis factor-α release.

Authors:  Adam Mor; Ofer Ben-Moshe; Yoseph A Mekori; Yoel Kloog
Journal:  Inflammation       Date:  2011-10       Impact factor: 4.092

5.  [Update on meat allergy. α-Gal: a new epitope, a new entity?].

Authors:  U Jappe
Journal:  Hautarzt       Date:  2012-04       Impact factor: 0.751

6.  Technical advance: soluble OX40 molecule mimics regulatory T cell modulatory activity on FcεRI-dependent mast cell degranulation.

Authors:  Riccardo Sibilano; Giorgia Gri; Barbara Frossi; Claudio Tripodo; Ryo Suzuki; Juan Rivera; Andrew S MacDonald; Carlo E Pucillo
Journal:  J Leukoc Biol       Date:  2011-06-07       Impact factor: 4.962

7.  IL-25 and CD4(+) TH2 cells enhance type 2 innate lymphoid cell-derived IL-13 production, which promotes IgE-mediated experimental food allergy.

Authors:  Jee-Boong Lee; Chun-Yu Chen; Bo Liu; Luke Mugge; Pornpimon Angkasekwinai; Valeria Facchinetti; Chen Dong; Yong-Jun Liu; Marc E Rothenberg; Simon P Hogan; Fred D Finkelman; Yui-Hsi Wang
Journal:  J Allergy Clin Immunol       Date:  2015-11-10       Impact factor: 10.793

8.  World Allergy Organization (WAO) Diagnosis and Rationale for Action against Cow's Milk Allergy (DRACMA) Guidelines.

Authors:  Alessandro Fiocchi; Jan Brozek; Holger Schünemann; Sami L Bahna; Andrea von Berg; Kirsten Beyer; Martin Bozzola; Julia Bradsher; Enrico Compalati; Motohiro Ebisawa; Maria Antonieta Guzman; Haiqi Li; Ralf G Heine; Paul Keith; Gideon Lack; Massimo Landi; Alberto Martelli; Fabienne Rancé; Hugh Sampson; Airton Stein; Luigi Terracciano; Stefan Vieths
Journal:  World Allergy Organ J       Date:  2010-04-23       Impact factor: 4.084

9.  Usefulness of nBos d 4, 5 and nBos d 8 Specific IgE Antibodies in Cow's Milk Allergic Children.

Authors:  Anna Cingolani; Sabrina Di Pillo; Marzia Cerasa; Daniele Rapino; Nicola Pietro Consilvio; Marina Attanasi; Alessandra Scaparrotta; M Loredana Marcovecchio; Angelika Mohn; Francesco Chiarelli
Journal:  Allergy Asthma Immunol Res       Date:  2013-11-08       Impact factor: 5.764

10.  Successful prevention of recurrent anaphylactic events with anti-immunoglobulin E therapy.

Authors:  Jaechun Lee
Journal:  Asia Pac Allergy       Date:  2014-04-29
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.